Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 16Terminated 2Recruiting 2Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Breast 1

Conditions

Neoplasm Metastasis 1Breast Neoplasms 1Advanced Non-Small Cell Lung Cancer 1

Interventions

Cyclophosphamide 391Carboplatin 344Gemcitabine 332pembrolizumab 331Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 287Bevacizumab 253Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 190fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 134Cetuximab 130fludarabine phosphate 129Bortezomib 129Lenalidomide 126Filgrastim 120Erlotinib Hydrochloride 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × WW Domain-Containing Oxidoreductase × Clear all
NCT00083993 2011-11-08

Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 3 Terminated
1,236 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00064636 2005-06-24

Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Millennium Pharmaceuticals, Inc.

Phase 1 Terminated
46 enrolled
Other solid neoplasmThoracic

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡